Dr Reddy's shares tank nearly 11% after US District Court's decision on sale of product
Shares of Dr Reddy's Laboratories on Monday slumped nearly 11 percent following a decision made by the District Court of New Jersey with respect to further sale and commercialisation of its product in the US


Representational pic. GettyImages[/caption]On NSE, shares of the company cracked 10.77 percent to Rs 2,069.95.Dr Reddy's Lab on Saturday said it will appeal the decision of the US District Court of New Jersey regarding further sale and commercialisation of its Buprenorphine and Naloxone sublingual film in America."The company disagrees with the court's decision, and will vigorously appeal it," Dr Reddy's said in a BSE filing.The company intends to appeal the decision made by the US District Court of New Jersey in a preliminary injunction hearing with respect to further sale and commercialisation of its product in the US, it added.The product is indicated for the treatment of opioid dependence.

India remains among fastest-growing major economies despite global uncertainty, says RBI Bulletin
Iran war could cut global growth by more than half: World Bank’s chief economist Indermit Gill
Brent crude climbs to $94 as analysts expect oil prices to stay in $90–100 range
UK inflation cools further to 2.6% in June as transport and food prices ease
India's gem and jewellery exports jump 26.5% in June on stronger global demand

